Robertson R P, Baylink D J, Metz S A, Cummings K B
J Clin Endocrinol Metab. 1976 Dec;43(6):1330-5. doi: 10.1210/jcem-43-6-1330.
Circulating levels of immunoreactive (i) PGE, calcium and parathyroid hormone (iPTH) were examined in 21 patients with neoplasia and 3 patients with primary hyperparathyroidism. Plasma iPGE was elevated in 4 of 11 hypercalcemic cancer patients; all extracts of liver metastases obtained from 3 of these 4 patients had elevated iPGE levels (metastases = 19.43 +/- 3.43, n = 11; normal liver = 2.04 +/- 0.23; ng/g tissue, x +/- SE, P less than .001). In contrast, only one of 10 normocalcemic cancer patients and none of 3 hyperparathyroid patients had elevated plasma iPGE. There were no apparent relationships between the presence of metastases and either hypercalcemia or elevations of plasma iPGE. Serum iPTH levels were undetectable or below the mean of the normal range in 19 of 21 cancer patients; only the three hyperparathyroid patients had elevated levels. Seven hypercalcemic patients were treated with indomethacin; plasma iPGE decreased in 6 (-34 +/- 10% decrement, n = 6, P less than .01). Decreases in serum calcium occurred only in those patients (2 of 6) who had abnormally elevated plasma iPGE prior to the therapy. It is concluded that plasma iPGE elevations are found in some cancer patients, especially those with hypercalcemia, and that this marker may identify those patients who will respond to indomethacin treatment.
检测了21例肿瘤患者和3例原发性甲状旁腺功能亢进患者的免疫反应性前列腺素E（iPGE）、钙和甲状旁腺激素（iPTH）的循环水平。11例高钙血症癌症患者中有4例血浆iPGE升高；从这4例患者中的3例获取的肝转移瘤提取物的iPGE水平均升高（转移瘤=19.43±3.43，n=11；正常肝脏=2.04±0.23；ng/g组织，x±SE，P<0.001）。相比之下，10例血钙正常的癌症患者中只有1例血浆iPGE升高，3例甲状旁腺功能亢进患者中无一例血浆iPGE升高。转移瘤的存在与高钙血症或血浆iPGE升高之间没有明显关系。21例癌症患者中有19例血清iPTH水平检测不到或低于正常范围均值；只有3例甲状旁腺功能亢进患者的水平升高。7例高钙血症患者接受了吲哚美辛治疗；6例患者的血浆iPGE下降（下降幅度为-34±10%，n=6，P<0.01）。只有那些在治疗前血浆iPGE异常升高的患者（6例中的2例）血清钙有所下降。结论是，一些癌症患者，尤其是高钙血症患者，血浆iPGE会升高，并且该标志物可能识别出那些对吲哚美辛治疗有反应的患者。
